Cargando…

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations

Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is implicated in cancer and DNA damage response (DDR) pathways are in place against this to maintain genomic stability. Impaired DDR pathways play a role in prostate carcinogenesis and germline or somatic mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Sidrah, Rachmat, Rachelle, Enyioma, Synthia, Ghose, Aruni, Revythis, Antonios, Boussios, Stergios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657599/ https://www.ncbi.nlm.nih.gov/pubmed/34884434 http://dx.doi.org/10.3390/ijms222312628

Ejemplares similares

The Experience of a Single NHS England Trust on the Impact of the COVID-19 Pandemic on Junior and Middle-Grade Doctors: What Is Next?
por: Revythis, Antonios, et al.
Publicado: (2021)

Cancer-Associated Thrombosis: A New Light on an Old Story
por: Shah, Sidrah, et al.
Publicado: (2021)

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
por: Boussios, Stergios, et al.
Publicado: (2022)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study
por: Vassiliou, Anna, et al.
Publicado: (2023)

Unraveling the Wide Spectrum of Melanoma Biomarkers
por: Revythis, Antonios, et al.
Publicado: (2021)

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
por: Ghose, Aruni, et al.
Publicado: (2021)

BRCA mutation in ovarian cancer: testing, implications and treatment considerations
por: Neff, Robert T., et al.
Publicado: (2017)

Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
por: Shah, Sidrah, et al.
Publicado: (2022)

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
por: Ioannidou, Evangelia, et al.
Publicado: (2021)

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
por: Ghose, Aruni, et al.
Publicado: (2022)

COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
por: Mahajan, Ishika, et al.
Publicado: (2022)

From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
por: Mathew, Beatrice Gadiel, et al.
Publicado: (2023)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
por: Cheung, Alison, et al.
Publicado: (2022)

Efficacy and Safety of COVID-19 Vaccines—An Update
por: Sharma, Eshani, et al.
Publicado: (2022)

Impact of COVID-19 on cancer services and patients’ outcomes: a retrospective single-center study
por: Sain, Baijaeek, et al.
Publicado: (2023)

Aberrations of DNA Repair Pathways in Prostate Cancer—The State of the Art
por: Boussios, Stergios, et al.
Publicado: (2023)

Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
por: Ghose, Aruni, et al.
Publicado: (2022)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Exosomes in the Diagnosis and Treatment of Renal Cell Cancer
por: Boussios, Stergios, et al.
Publicado: (2023)

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
por: Saxby, Helen, et al.
Publicado: (2020)

Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer
por: Saxby, Helen, et al.
Publicado: (2022)

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
por: Linares, Christian A., et al.
Publicado: (2023)

Epilepsy and Diagnostic Dilemmas: The Role of Language and Speech-Related Seizures
por: Papadopoulou, Soultana, et al.
Publicado: (2022)

Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre
por: Sain, Baijaeek, et al.
Publicado: (2023)

Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK
por: Shah, Sidrah, et al.
Publicado: (2021)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation
por: Han, Hyunho, et al.
Publicado: (2022)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
por: Madariaga, Ainhoa, et al.
Publicado: (2019)

Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
por: Ponder, B
Publicado: (2000)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Ovarian cancer: state of the art and perspectives of clinical research
por: Boussios, Stergios, et al.
Publicado: (2020)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Rapid progression of prostate cancer in men with a BRCA2 mutation
por: Narod, S A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_raoe91r2dfp9c1lipqc0uj241a